BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq:
NSTK - News) announced that having acquired shareholder approval, effective
today the Company has changed its name to MDRNA, Inc. (“MDRNA”). MDRNA will
leverage its scientific and intellectual property (IP) position surrounding
the research, development and delivery of Dicer substrates and “Meroduplex”
(mdRNA) RNA interference (RNAi) drug candidates to build an industry-leading
position in the development and commercialization of RNAi-based therapeutics.
In addition to its license through the City of Hope to Dicer substrate IP, MDRNA
will leverage its portfolio of delivery IP, including an issued patent on the
“Trp Cage” phage display library for generating tissue-homing peptides. Effective
Wednesday, June 11, 2008, the Company's stock will trade on NASDAQ under the
As part of its new corporate and scientific focus, MDRNA has named J. Michael
French, formerly of Sirna Therapeutics, as Chief Executive Officer, effective
June 23, 2008. Mr. French succeeds Steven C. Quay, M.D., Ph.D. Dr. Quay has
been appointed Chief Scientific Officer and Chairman of MDRNA's Scientific Advisory
Board and will remain Chairman of the Board of Directors.
“I am thrilled to join MDRNA and be a part of this truly exciting science,”
stated Mr. French. “I look forward to working with this exceptional MDRNA team
to establish an industry leading position in the emerging field of RNAi. With
Dr. Quay leading an outstanding group of young, bright and energetic researchers,
I believe we will make significant strides in the coming months to further demonstrate
efficient delivery and therapeutic effectiveness of our RNAi-based therapeutics.
In establishing an industry-leading position, we are aggressively pursuing partnerships
with major biopharmaceutical companies while advancing a pipeline of pre-clinical
product candidates. We look forward to reporting our progress over the next
Dr. Quay commented, “I am looking forward to focusing my attention on the further
development of our core delivery technologies and the rapid advancement of our
preclinical pipeline of novel MDRNAi and siRNA drug candidates toward human
clinical development. This is an exciting time for me and our world-class scientific
team as we continue to capitalize on the breakthroughs we have made in developing
safe and effective RNAi-based therapeutics.”
MDRNA is currently pursuing pre-clinical RNAi programs in influenza and rheumatoid
arthritis, from which it will identify appropriate target candidates for partnering
and clinical development. The Company believes it has been building one of the
broadest and deepest patent estates in the RNAi field, with more than 260 filed
patents addressing 144 gene sequences including numerous disease-validated targets.
Concurrently, the Company is seeking to monetize its legacy nasal drug delivery
business through licensing, partnering or acquisition of its Phase II intranasal
programs, including its ultra rapid acting insulin for diabetes, Peptide YY3-36
for obesity and parathyroid hormone (PTH1-34) for osteoporosis.
Mr. French was Senior Vice President of Corporate Development at Sirna Therapeutics,
one of the leading RNAi companies, from 2005 until 2007 when the company was
acquired by Merck. Earlier, Mr. French was Chief Business Officer for Entelos,
Inc., a pre-IPO biotechnology company and previously held a variety of positions
at other healthcare companies, including HealthIQ, Farma Biagini and Bayer Pharmaceuticals.
He also served for 13 years in the United States Army and Army Reserve. Mr.
French holds a M.S. degree in physiology and biophysics from Georgetown University
and a B.S. degree in aerospace engineering from the United States Military Academy.
About Dicer Substrates and Meroduplex Technology
Dicer substrates are oligonucleotides that are slightly longer than standard
“RISC” substrates and are processed by the Dicer enzyme into the siRNA strands
that activate the RNAi pathway. MDRNA is utilizing the unique characteristics
of Dicer substrates to develop novel delivery approaches for safe and effective
systemic delivery of RNAi-based therapeutics.
Meroduplex, or “mdRNA”, is a next-generation oligonucleotide technology being
pioneered and developed by MDRNA, Inc. as a platform approach for the development
of potentially safer and more efficacious RNAi-based therapeutics.
About MDRNA, Inc.
MDRNA, Inc. is a biotechnology company developing RNAi-based therapeutics.
The Company's primary focus is on the safe and effective delivery of MDRNAi
and siRNA drug candidates for the treatment of a wide range of human diseases,
including inflammation, viral infections, cancer and metabolic disorders. MDRNA
will continue to leverage its expertise and capabilities toward innovation in
novel and useful RNA-based compositions in order to increase the value proposition
of MDRNA to investors and partners. Additional information about MDRNA, Inc.
is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within
the meaning of Federal Securities laws that are subject to certain risks and
uncertainties and involve factors that may cause actual results to differ materially
from those projected or suggested. Factors that could cause actual results to
differ materially from those in forward-looking statements include, but are
not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional
funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain
manufacturing, research, development and commercialization partners; (iii) the
ability of MDRNA, a subsidiary and/or a partner to successfully complete product
research and development, including preclinical and clinical studies and commercialization;
(iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a
partner to develop and commercialize products that can compete favorably with
those of competitors. Additional factors that could cause actual results to
differ materially from those projected or suggested in any forward-looking statements
are contained in MDRNA's most recent periodic reports on Form 10-K and Form
10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes
no obligation to update and supplement forward-looking statements because of
Matthew D. Haines, 212-209-3874
Senior Director, Investor Relations and
Lippert/Heilshorn & Associates, Inc.
Jules Abraham, 212-838-3777
Source: MDRNA, Inc.